U.S. pharma huge copyright scrapped two experimental weight loss capsules previous year—a the moment-everyday pill, lotiglipron, due to elevated liver enzymes as well as a 2 times-everyday capsule, danuglipron, due to robust Unwanted effects—but CEO Albert Bourla has said the company